These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 29522576)

  • 61. Evaluation of the Etest GRD for the detection of Staphylococcus aureus with reduced susceptibility to glycopeptides.
    Leonard SN; Rossi KL; Newton KL; Rybak MJ
    J Antimicrob Chemother; 2009 Mar; 63(3):489-92. PubMed ID: 19136530
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Genotype-specific prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus in Asian countries.
    Chung DR; Lee C; Kang YR; Baek JY; Kim SH; Ha YE; Kang CI; Peck KR; Lee NY; Song JH
    Int J Antimicrob Agents; 2015 Sep; 46(3):338-41. PubMed ID: 25982914
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Heterogeneous vancomycin resistance in Staphylococcus aureus does not predict development of vancomycin resistance upon vancomycin pressure.
    Gaillard T; Dupieux-Chabert C; Butin M; Dumitrescu O; Naceur O; Bouveyron C; Martra A; Bes M; Tristan A; Vandenesch F; Lina G; Laurent F; Rasigade JP
    J Antimicrob Chemother; 2022 Mar; 77(4):1032-1035. PubMed ID: 35022718
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Decreasing prevalence of isolates with vancomycin heteroresistance and vancomycin minimum inhibitory concentrations ≥2 mg/L in methicillin-resistant Staphylococcus aureus over 11 years: potential impact of vancomycin treatment guidelines.
    Khatib R; Sharma M; Johnson LB; Riederer K; Shemes S; Szpunar S
    Diagn Microbiol Infect Dis; 2015 Jul; 82(3):245-8. PubMed ID: 25935628
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Multidrug and vancomycin resistance among clinical isolates of
    Olufunmiso O; Tolulope I; Roger C
    Afr Health Sci; 2017 Sep; 17(3):797-807. PubMed ID: 29085408
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Global distribution of heterogeneous vancomycin-intermediate Staphylococcus aureus strains (1997-2021): a systematic review and meta-analysis.
    Keikha M; Karbalaei M
    J Glob Antimicrob Resist; 2024 Jun; 37():11-21. PubMed ID: 38336227
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Systematic Review and Meta-Analysis of the Epidemiology of Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolates.
    Zhang S; Sun X; Chang W; Dai Y; Ma X
    PLoS One; 2015; 10(8):e0136082. PubMed ID: 26287490
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Investigation of glycopeptide resistance in methicillin resistant staphylococcal isolates].
    Hoşgör Limoncu M; Ermertcan S; Taşli H; Kurutepe S
    Mikrobiyol Bul; 2007 Oct; 41(4):511-6. PubMed ID: 18173069
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Primary research on detecting bacteria drug resistance by matrix-assisted laxer desorption ionization time-of-flight mass spectrometry].
    Shi G; Sun Z; Chen X
    Wei Sheng Yan Jiu; 2008 Jan; 37(1):82-5. PubMed ID: 18421873
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Daptomycin bactericidal activity and correlation between disk and broth microdilution method results in testing of Staphylococcus aureus strains with decreased susceptibility to vancomycin.
    Sader HS; Fritsche TR; Jones RN
    Antimicrob Agents Chemother; 2006 Jul; 50(7):2330-6. PubMed ID: 16801409
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
    Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ
    J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Elevated vancomycin minimum inhibitory concentrations among methicillin-resistant Staphylococcus aureus isolated from patients with ventilator-associated pneumonia at a Connecticut hospital.
    Kuti JL; Nicasio AM; Sutherland CA; Nicolau DP
    Conn Med; 2009; 73(6):337-40. PubMed ID: 19637663
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The incidence of heterogeneous vancomycin-intermediate Staphylococcus aureus correlated with increase of vancomycin MIC.
    Chen H; Liu Y; Sun W; Chen M; Wang H
    Diagn Microbiol Infect Dis; 2011 Nov; 71(3):301-3. PubMed ID: 21856109
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus strains with reduced susceptibility to daptomycin, linezolid or vancomycin, and strains with defined SCCmec types.
    Farrell DJ; Flamm RK; Sader HS; Jones RN
    Int J Antimicrob Agents; 2014 Apr; 43(4):323-7. PubMed ID: 24411474
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Culture conditions and sample preparation methods affect spectrum quality and reproducibility during profiling of Staphylococcus aureus with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.
    Goldstein JE; Zhang L; Borror CM; Rago JV; Sandrin TR
    Lett Appl Microbiol; 2013 Aug; 57(2):144-50. PubMed ID: 23617594
    [TBL] [Abstract][Full Text] [Related]  

  • 76. MALDI-TOF MS typing of a nosocomial methicillin-resistant Staphylococcus aureus outbreak in a neonatal intensive care unit.
    Steensels D; Deplano A; Denis O; Simon A; Verroken A
    Acta Clin Belg; 2017 Aug; 72(4):219-225. PubMed ID: 27344933
    [TBL] [Abstract][Full Text] [Related]  

  • 77. In vitro synergistic effects of various combinations of vancomycin and non-beta-lactams against Staphylococcus aureus with reduced susceptibility to vancomycin.
    Kang YR; Chung DR; Kim J; Baek JY; Kim SH; Ha YE; Kang CI; Peck KR; Song JH
    Diagn Microbiol Infect Dis; 2016 Nov; 86(3):293-299. PubMed ID: 27591174
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Incidence and characteristics of vancomycin nonsusceptible strains of methicillin-resistant Staphylococcus aureus at Hershey Medical Center.
    Kosowska-Shick K; Ednie LM; McGhee P; Smith K; Todd CD; Wehler A; Appelbaum PC
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4510-3. PubMed ID: 18838583
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Prevalence and Clinical Impact of Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolated From Hospitalized Patients.
    Koh YR; Kim KH; Chang CL; Yi J
    Ann Lab Med; 2016 May; 36(3):235-43. PubMed ID: 26915612
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Ceftaroline pharmacodynamic activity versus community-associated and healthcare-associated methicillin-resistant Staphylococcus aureus, heteroresistant vancomycin-intermediate S. aureus, vancomycin-intermediate S. aureus and vancomycin-resistant S. aureus using an in vitro model.
    Zhanel GG; Rossnagel E; Nichol K; Cox L; Karlowsky JA; Zelenitsky S; Noreddin AM; Hoban DJ
    J Antimicrob Chemother; 2011 Jun; 66(6):1301-5. PubMed ID: 21429940
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.